Pharma and Healthcare Insight

Pharma & Healthcare Insight brings you analysis of regional trends, regulatory changes, projects and investments plus competitive intelligence on the growth strategies of leading companies in the sector

See Prices or Subscribe

Key stories from this month's issue...

Industry Trend Analysis - Diabetes Epidemic Will Boost Commercial Opportunities For Drugmakers And Device Companies - AUG 2017

Americas June 2017 / Mexico / Industry

Mexico's diabetes epidemic will continue to provide revenue-earning opportunities for multinational pharmaceutical and device manufacturers. Rooted in continued unhealthy behaviour, the escalating diabetes-related health expenditure will drive the enforcement of preventative measures and the use of treatments in both the private and public sectors. Further government action, motivated by the positive outcomes of the tax on sugary drinks, will help attenuate the prevalence of the disease in Mexico.


Industry Trend Analysis - A Recap On The Pharmaceuticals & Healthcare Outlook For 2017: Asia Pacific - AUG 2017

Asia June 2017 / Asia / Industry

The Asia Pacific (APAC) pharmaceutical market will see modest growth in 2017. Ongoing trends such as the roll-out of universal healthcare and advances by private healthcare providers are expected to continue, shaping opportunities for the region. In 2017, APAC will be further impacted by the failure to pass the Trans-Pacific Partnership in 2017. In addition, the pricing environment in the APAC region will become more dynamic as governments seek to introduce more measures to control spending while still meeting the demand for high-value pharmaceuticals.


Industry Trend Analysis - Cancer Vaccines Remain Viable Immuno-Oncology Target - AUG 2017

Emerging Europe June 2017 / Europe / Industry

Positive results for a cancer vaccine highlight that this segment of immuno-oncology is still viable. Vaxon Biotech is taking a non-personalised approach, which will limit manufacturing costs, and aid in capturing market share if it gains approval. The small biotech will attract the interest of larger firms, either through development agreements or financing.


Industry Trend Analysis - Diverse Pharmaceutical Environment To Determine Drugmaker Opportunities - AUG 2017

Middle East & Africa June 2017 / Middle East / Industry

The pharmaceutical markets in the MENA region will be shaped by a combination of trends over the coming years. The MENA region is characterized by an unfavourable demographic profile, with the risks most pronounced in countries with large youth populations and weak growth outlooks. Rapid population growth bodes well for drugmaker opportunities over the long-term, yet this potential is somewhat marred by the negative impact of small pensionable populations limiting medicine sales growth.


Industry Trend Analysis - Macron's Focus On ONDAM To Continue To Challenge Drugmakers - AUG 2017

Western Europe June 2017 / France / Industry

France's pharmaceuticals and healthcare market will benefit from an uptick in economic growth over Macron's presidential term, supported by a pro-business agenda and lower corporation tax. That said, with public debt ballooning to over 97.0% of GDP at the end of 2016, the French government will have to consolidate its budget. Over the long term, cost-containment will remain high on the government's agenda and the pharmaceutical market will remain a target of cost containment._x000d_